Conference Day Two
Wednesday June 18, 2025

8:25 am Chair’s Opening Remarks

Spearheading Target Validation to Demonstrate Safety & Efficacy for a Novel Target Class

8:30 am An End-to-End Discovery & Validation Platform for Dark Genome Targets

Synopsis

  • Enhancing discovery of dark genome targets by overcoming characterization challenges for low expression targets
  • Developing optimized assays and tools to detect and quantify dark genome-derived transcripts and peptides
  • Identifying optimal modality with deep iterative screening

9:00 am Advancing LINE-1 Reverse Transcriptase Inhibitors in Autoimmune & Neurodegenerative Diseases

  • Sarah Knutson Senior Director, Early Discovery, ROME Therapeutics

Synopsis

  • Repeat elements like LINE-1 make up most of our DNA, and their expression is silenced in healthy cells
  • When aberrantly expressed in disease, LINE-1 reverse transcriptase (RT) drives interferon signaling and “sterile inflammation”
  • LINE-1 RT inhibitors inhibit tissue interferon signaling and inflammation. They target large patient populations and have the potential to be non-immune suppressive therapies

9:30 am Dark Antigens® – Novel Tumor-Specific Targets for Cancer Immunotherapy

Synopsis

  • Mining the dark genome to uncover regions encoding putative Dark Antigens®
  • Integrating large-scale, multiomic data to identify and validate cancer-specific Dark Antigens®
  • Characterizing Dark Antigens® with broad therapeutic potential

10:00 am Morning Refreshment Break & Networking

The Untrodden Path: Paving a Smooth Road to the Clinic to Ensure Translatable Success

11:00 am Translating Discovery of Novel LncRNA Targets into Clinical Programs

  • Samir Ounzain Co-Founder & Chief Executive Officer & Director, Board, HAYA Therapeutics

Synopsis

  • Discovering high-value LncRNA targets to reprogram diseased cell states
  • Understanding underlying LncRNA and target biology to curate preclinical and clinical strategy
  • Building smooth drug development strategy and uncovering robust biomarkers for smooth recruitment and progression

11:15 am Bringing Dark Genome-Targeted Personalized Cancer Vaccines to the Clinic

  • Eric Halioua President & Chief Executive Officer, PDC*line Pharma

Synopsis

  • A new class of cancer vaccines based on an off-the-shelf antigen-presenting cell line (PDC*line)
  • Harnessing the PDC*line Pharma platform to develop effective personalized cancer vaccines (PDC*neo)
  • Unlocking the dark genome: discovering novel neoantigen targets for cancer immunotherapy

12:00 pm Interactive Workshop: Sailing Unchartered Waters: Building the Development Roadmap for the Dark Genome to Navigate Smooth Progression of Novel Therapeutics

Synopsis

  • Defining the discovery, preclinical and clinical roadmap for a novel class of targets to ensure regulatory compliance, efficient translatability and smooth progression
  • Outline considerations for modality and indication selection to influence target prioritization, delivery methods and safety
  • Determining key success factors for the emerging field, including data sharing, technological advances and funding, to mitigate risk for novel therapeutic development
  • Discussing strategies to build awareness, trust and engagement alongside robust funding and collaboration strategies to safeguard the success of the field

1:15 pm Lunch Break & Networking

Advancing Tools & Technologies to Mine Deeper into the Dark Genome

2:15 pm Unravelling Disease Complexity at the Isoform Frontier

  • Adam Cribbs Co-Founder & Chief Technology Officer, Entelo Bio

Synopsis

  • Bringing single-cell and spatial resolution to 3rd generation -omics approaches
  • Challenges and opportunities in bioinformatics and machine learning with these new data types
  • Applications across cancer and chronic disease

2:45 pm A Robust Computational Approach to Unraveling the Role of Highly Repetitive Elements in Human Health & Disease

  • Liyang Diao Director - Data Science, ROME Therapeutics

Synopsis

  • Highly repetitive elements comprise > 50% of the human genome, while canonical protein-coding genes comprise only ~2%
  • Naive approaches to the quantification of the expression of these elements fail to address their unique challenges, resulting in estimates that obscure their association with disease
  • ROME’s custom ML algorithms and curated databases enable highly accurate locus level quantification of expression and activity of these repetitive elements, supporting their relevance in disease

3:15 pm Interpreting the Code for RNA Splicing to Predict Activity in Disease

  • Chris Burge Professor, Massachusetts Institute of Technology

Synopsis

  • Deciphering alternative splicing to characterize isoforms with targeting potential
  • Leveraging transcriptome analysis to determine splicing patterns in non-coding RNA
  • Mapping RNA binding activity to understand mRNA localization and microRNA regulation

3:45 pm Harnessing Immunopeptidomics Techniques to Uncover Hidden Peptides

  • Robert Salzler Bioanalytical, Biomarker Technologies & Immunopeptidomics Professional, Regeneron

Synopsis

  • Conducting immunopeptidomics experiments to understand the interplay between genome, transcriptome and proteome
  • Enhancing computational tools to analyze large datasets generated by immunopeptidomics

4:15 pm Close of Conference Day Two